Plasma Cell Leukemia
43
18
20
13
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
4.7%
2 terminated out of 43 trials
86.7%
+0.1% vs benchmark
0%
0 trials in Phase 3/4
69%
9 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 13 completed trials
Clinical Trials (43)
Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial
High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
The Norwegian Immunotherapy in Multiple Myeloma Study
Allo HSCT Using RIC and PTCy for Hematological Diseases
A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Expanded Access to Venetoclax
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
European Myeloma Network (EMN) Sample Project
Registry for Adults With Plasma Cell Disorders (PCD's)
Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia
A Study of CT0596 in Plasma Cell Leukemia